ERBB2 and neoplasm: The authors demonstrate that their platform enables clinicians to intuitively construct patient cohorts based on complex criteria, such as tumor biomarker status (e.g., HER2), immune-related checkpoint-inhibitor toxicities, and detailed symptomatology, without requiring coding expertise.